arXiv · 2505.18920
Sensitivity analysis-guided model reduction of a mathematical model of pembrolizumab therapy for de novo metastatic MSI-H/dMMR colorectal cancer
Abstract
Colorectal cancer (CRC) is the third most commonly diagnosed cancer worldwide and the leading cause of cancer-related deaths in adults under 55, involving a complex interplay of biological processes such as dendritic cell (DC) maturation and migration, T cell activation and proliferation, cytokine production, and T cell and natural killer (NK) cell-mediated cancer cell killing. Microsatellite instability-high (MSI-H) CRC and deficient mismatch repair (dMMR) CRC constitute 15% of all CRC and 4% of metastatic CRC, and exhibit remarkable responsiveness to immunotherapy, especially with PD-1 inhibitors such as pembrolizumab. Mathematical models of the underlying immunobiology and the interactions underpinning immune checkpoint blockade offer mechanistic insights into tumour--immune dynamics and provide avenues for treatment optimisation and the identification of novel therapeutic targets. We used our data-driven model of de novo metastatic MSI-H/dMMR CRC (dnmMCRC) and performed sensitivity analysis-guided model reduction using the Fourier amplitude sensitivity testing (FAST) and extended FAST (EFAST) methods. In this work, we constructed two simplified models of dnmMCRC: one that faithfully reproduces all of the original model's trajectories, and a second, minimal model that accurately replicates the original dynamics while being highly extensible for future inclusion of additional components to explore various aspects of the anti-tumour immune response. Together, these resulting models offer a tractable foundation for future theoretical and computational studies of immune checkpoint blockade, avoiding unnecessary complexity while preserving mechanistic interpretability.
Explore related subjects
Keep this discovery
Explore connections, maps & timelines
Georgio Hawi, Peter S. Kim, Peter P. Lee. 2025-05-25. Sensitivity analysis-guided model reduction of a mathematical model of pembrolizumab therapy for de novo metastatic MSI-H/dMMR colorectal cancer. https://arxiv.org/abs/2505.18920
Cite the original work for its findings. Save a collection to share your selection of sources.